News FAMHP

The FPS Public Health and the FAMHP invite you to participate in the public consultation on a clinical trial of the genetically modified medicine GNT0004 for the treatment of Duchenne Muscular Dystrophy. The public consultation will take place from March 9th to April 8th 2026.

The FAMHP is launching HemoVigilance, a new online application for reporting serious adverse reactions related to the donation or transfusion of blood and blood components. The application also allows users to report any serious adverse incidents that have an impact on the quality and safety of labile blood components to the FAMHP.

During its February 2026 meeting, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency recommended the withdrawal of medicines containing levamisole from the EU market. These medicinal products are not marketed in Belgium, but are included in the World Health Organisation list of essential medicines.

The FPS Public Health and the FAMHP invite you to participate in the public consultation on a clinical trial of the genetically modified medicine AAVB-039 for the treatment of Stargardt Disease. The public consultation will take place from February 28th to March 30th 2026.

Due to a delay in production, the oncological medicinal product Holoxan 1 g powder for solution for injection for intravenous use has been unavailable since 28 January 2026.

In 2025, the FAMHP introduced a new web form for questions on variations and renewals. This form should make it easier and more efficient to submit your questions. Please let us know what you think so we can continue to improve it.

The FPS Public Health and the FAMHP invite you to participate in the public consultation on a clinical trial of the genetically modified medicine VTx-002 for the treatment of Amyotrophic Lateral Sclerosis (ALS). The public consultation will take place from February 9th to March 11th, 2026.

Following several cases of overdose among teenagers in Belgium, linked to a challenge circulating on social media, the FAMHP reminds everyone that excessive consumption of paracetamol can have serious effects on health.

Oral methotrexate can cause serious side effects in the event of overdose. Despite the measures put in place, cases of accidental overdose continue to be reported. Most cases result from taking the medicine too often compared to the prescription. For the treatment of inflammatory diseases, oral methotrexate should only be taken once a week, always on the same day.

Medication errors are a major public health problem, particularly among the elderly. Complex treatments, polypharmacy and age-related changes increase the risks. Better prevention and appropriate support are essential to ensure that medicines are used safely and effectively.